Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — J.P. Morgan Healthcare Conference 2025
20 slides from Crinetics Pharmaceuticals's conference presentation, Jan 14, 2025
Slide 1: January 2025 J.P. Morgan Healthcare Conference
January 2025 J.P. Morgan Healthcare Conference ® Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements.
Slide 3: Building a Premier, Endocrine-Focused Global Biopharmaceutical Company
Building a Premier, Endocrine-Focused Global Biopharmaceutical Company to Improve the Lives of Patients Discovering, Developing, and Commercializing the Next Generation of Therapeutics for Patients with Endocrine Diseases
Slide 4: 2024: Solid Track Record of Success
2024: Solid Track Record of Success CONFIDENTIAL Other Pipeline Achievements Atumelnant Validation Positive Topline Results in Phase 2 Studies in Congenital Adrenal Hyperplasia and Initial Results in Cushing’s Disease Strengthened Balance Sheet to ~$1.4B Pro Forma Cash and Investments1 Paltusotine M
Slide 5: Transforming Endocrine Disease Treatment from Discovery to Commercialization
Transforming Endocrine Disease Treatment from Discovery to Commercialization… Proven Development Commercial Execution Demonstrated execution with 5 positive global Phase 2 or 3 readouts in ~2 years and first NDA submitted Steady stream of upcoming clinical catalysts Building global commercial capabi
Slide 6: Acromegaly Patients Face Significant Unmet Need, Presenting a Compelling Market Opportunity
Acromegaly Patients Face Significant Unmet Need, Presenting a Compelling Market Opportunity Had acromegaly symptoms worsen at end of SRL injection cycle2 Felt upset for being dependent on others for treatment1 “It's urgent because symptoms affect my quality of life, affect my relationships, affect m
Slide 7: Paltusotine Achieved Rapid, Reliable and Consistent Biochemical Control in Acromegaly
In Phase 3 Studies, Investigational Paltusotine Achieved Rapid, Reliable and Consistent Biochemical Control in Acromegaly IGF-1 values measured prior to rescue or discontinuation are carried forward *Paltusotine is an investigational drug. Commercial launch is dependent on regulatory approval. In cl
Slide 8: Paltusotine Improved Acromegaly Symptom Control in Phase 3 Studies
Online Symptom Survey (n=31 on iSRLs) Symptom Exacerbation Rate (%) Paltusotine Screening 0-3 Months Treatment 3-6 Months Treatment 6-9 Months Treatment +4.6 -0.6 In Phase 3 Studies, Investigational Paltusotine Improved Acromegaly Symptom Control Data on File iSRL = injectable somatostatin receptor
Slide 9: Paltusotine Mission: Deliver next generation care to people with acromegaly
Paltusotine Mission: Deliver next generation care to people with acromegaly Paltusotine is an investigational drug. Commercial launch of paltusotine is dependent on regulatory approval. Reduce burden and improve control On Standard of Care Undertreated Drive treatment to target Untreated Educate and
Slide 10: CAH Affects ~17,000 Addressable Adult and Pediatric Patients in the US
CAH Affects ~17,000 Addressable Adult and Pediatric Patients in the US Treatment Goals in Adults with CAH Reduction of A4 and other androgens to address hyperandrogenism, which can manifest as excessive facial hair, acne and polycythemia Restore normal menstrual cycles and fertility in women Shrink
Slide 11: Atumelnant Demonstrated Rapid, Substantial and Sustained A4 Reductions
Atumelnant Demonstrated Rapid, Substantial and Sustained A4 Reductions, the Key Biomarker for CAH Disease Control Participants At Baseline: 40 mg N=11; 80 mg N=11; 120 mg N=6. Participants At Week 12: 40 mg N=10; 80 mg N=11; 120 mg N=6. CFB: change from baseline, LSM: Least-square-mean Across each c
Slide 12: Significant Clinical Improvements Achieved with Atumelnant Treatment
Significant Clinical Improvements Achieved with Atumelnant Treatment CAH Manifestations Achieved following 12 weeks of treatment with atumelnant Overproduction of androgens, and androgen precursors Normalization of A4 in many participants and substantial reduction in 17-OHP levels (across dose group
Slide 13: Atumelnant Vision: Healthier Hormone Levels for People Living with CAH
A single pill taken once a day, that eliminates excess ACTH driven adrenal activation and its clinical sequalae for people struggling with Congenital Adrenal Hyperplasia Normal A4 + GC High A4 + Normal GC High A4 + High GC Normal A4 + High GC Atumelnant Vision: Healthier Hormone Levels for People Li
Slide 14: Driving Next Wave of Innovation to Address Unmet Needs in Large Patient Populations
Neuroendocrine Tumors (NETs) Hyperparathyroidism Graves / TED ADPKD¹ SST2+ NDC (CRN09682) PTH antagonist TSH antagonist SST3 agonist 140K patients with SST2+ NETs 200K incident cases of symptomatic primary hyperparathyroidism 3M+ patients with Graves, many develop TED 300K+ patients with ADPKD SST2+
Slide 15: CRN09682 is Designed to Selectively Target and Deliver Cytotoxic Payload to SST2-Expressing Tumor Cells
CRN09682 is Designed to Selectively Target and Deliver Cytotoxic Payload to SST2-Expressing Tumor Cells MMAE: monomethyl auristatin E; tubulin inactivator; PROTAC: Proteolysis-targeting chimeras Stable in plasma Cleaved intracellularly Selective nonpeptide SST2 agonist High affinity and selectivity
Slide 16: IND Submission for CRN09682 Expected Early 2025 Based on Promising Preclinical Data
IND Submission for CRN09682 Expected Early 2025 Based on Promising Preclinical Data CRN09682 Efficacy study in NCI-H524 tumor model CRN09682 Selectively Delivers MMAE to Tumors With Minimal Systemic Exposure to Free MMAE in Mice CRN09682 Induces Rapid Regression of SST2+ Small Cell Lung Tumors in Nu
Slide 17: Continued Value Creation with Deep Pipeline of Transformative Drug Candidates
Continued Value Creation with Deep Pipeline of Transformative Drug Candidates SST: somatostatin receptor type; ACTH: adrenocorticotropic hormone; PTH: parathyroid hormone; ADPKD: Autosomal dominant polycystic kidney disease.; TSH: thyroid-stimulating hormone; TED: thyroid eye disease; GLP-1: glucago
Slide 18: Building a Premier Endocrine-Focused Global Biopharmaceutical Company
Building a Premier Endocrine-Focused Global Biopharmaceutical Company NDA: New drug application; CAH: Congenital adrenal hyperplasia; ADPKD: Autosomal Dominant Polycystic Kidney Disease; TED: Thyroid Eye Disease; NDC: Nonpeptide Drug Conjugate *Pending regulatory approval. **Pending clinical develop
Slide 19: Exploring New Frontiers With Our Science to Expand Patient Reach
Pituitary Acromegaly Pituitary Acromegaly Endocrinology-Adjacent Graves’ Disease Thyroid Ophthalmopathy Obesity Cushing’s Disease Congenital Adrenal Hyperplasia Carcinoid Syndrome Polycystic Kidney Disease Neuroendocrine & Other SST2+ Tumors Exploring New Frontiers With Our Science to Expand Patient
Slide 20: Thank You
| THANK YOU we, -Crinetics Pharmaceuticals
Crinetics Pharmaceuticals — J.P. Morgan Healthcare Conference 2025 on 6ix